Oppenheimer analyst Leland Gershell maintains $Biomarin Pharmaceutical (BMRN.US)$ with a hold rating.
According to TipRanks data, the analyst has a success rate of 37.7% and a total average return of 4.2% over the past year.
Furthermore, according to the comprehensive report, the opinions of $Biomarin Pharmaceutical (BMRN.US)$'s main analysts recently are as follows:
BioMarin delivered a robust financial quarter, with a slight increase in its guidance for both revenue and earnings. The valuation of the company's enzyme replacement therapy business is believed to be equal to or greater than the current trading level of the company's shares. The anticipation for BMN333, which is slated to enter clinical trials in early 2025, is high as it has the potential to be a major factor in maintaining market share in achondroplasia and may expand to additional indications where Voxzogo is under investigation.
BioMarin's quarterly financial outcomes indicated a surpassing of estimated top and bottom lines, with a modest increase in the fiscal 2024 forecast for all principal indicators. Analysts note that although Voxzogo's performance was below expectations, this shortfall was compensated by the stronger than anticipated outcomes from various offerings within the company's enzyme replacement therapy portfolio.
The assessment notes an appealing entry point for BioMarin at the current share value, highlighting the company's solid foundational business and the possibility for significant operating margin growth in the upcoming years.
Note:
TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.
Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.
TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.
奧本海默控股分析師Leland Gershell維持$拜瑪林製藥 (BMRN.US)$持有評級。
根據TipRanks數據顯示，該分析師近一年總勝率為37.7%，總平均回報率為4.2%。
此外，綜合報道，$拜瑪林製藥 (BMRN.US)$近期主要分析師觀點如下：
BioMarin交出了一個強勁的財政季度報告，營業收入和盈利的指引均略有增加。該公司酶替代療法業務的估值被認爲等同於或高於公司股票當前交易水平。對於計劃於2025年初進入臨床試驗的BMN333的期待很高，因爲它有潛力成爲在軟骨發育不全領域保持市場份額的主要因素，並可能擴展到Voxzogo正在接受調查的其他適應症。
BioMarin季度財務業績顯示超過了預期的銷售額和盈利，2024財年各主要因子預測略有增加。分析師指出，儘管Voxzogo的表現低於預期，但這一不足被公司酶替代療法組合中的多種產品的表現強於預期所彌補。
評估指出，BioMarin在當前股價具有吸引力的入場點，突出了公司堅實的基礎業務和未來幾年中營業利潤率增長的巨大可能性。
提示:
TipRanks為獨立第三方，提供金融分析師的分析數據，並計算分析師推薦的平均回報率和勝率。提供的信息並非投資建議，僅供参考。本文不對評級數據和報告的完整性與準確性做出認可、聲明或保證。
TipRanks提供每位分析師的星級，分析師星級代表分析師所有推薦的過往表現，通過分析師的總勝率和平均回報率综合計算得出，星星越多，則該分析師過往表現越優異，最高爲5颗星。
分析師總勝率為近一年分析師的評級成功次數占總評級次數的比率。評级的成功與否，取決於TipRanks的虚擬投資組合是否從該股票中產生正回報。
總平均回報率為基於分析師的初始評級創建虚擬投資組合，並根據評級變化對組合進行調整，在近一年中該投資組合所獲得的回報率。
